Propanc Health Group Corp (OTCMKTS:PPCH) could relate to ‘see-saw’ as far as its journey on the market is concerned. But, the development stage healthcare company is giving more emphasis on its business over its trading pattern. Last week, the company began the second stage POP1 research program in partnership with the University of Jaen, Spain. The goal of the research is to arrive at the anti-cancer effects and cellular mechanisms attached with proenzymes that help treat cancer.
Partnered With University of Jaen
The company’s another agenda behind the research is to find out new patentable drugs that could act as back compounds to the company’s main candidate, PRP. James Nathanielsz, Propanc Health Group Corp (OTCMKTS:PPCH)’s Chief Executive Officer said that Jaen, Granada, and Bath Universities have played a vital role in the company’s initial research. He noted that the Universities contributed tremendously to assist the company find out the accurate functioning of PRP and identify patentable opportunities.
Strategic plan
Nathanielsz reminded investors about the role played by Bath University in its last research, when the company had not only filed the patent but was able to publish chief scientific discoveries in a leading reviewed journal. He credited lead scientist, Dr. Macarena Paren in her work to bring the Research Institutions together.
Meanwhile, Nathanielsz said that the company is aggressively looking forward to screen and develop new compounds that could back up its lead drug, PRP. He added that the company aims to experiment and identify new treatment compounds in oncology, which at the same time, will complement the company’s other existing treatments. Nathanielsz called the plan as strategic move undertaken by the company.
As Propanc Health Group Corp (OTCMKTS:PPCH) pushes forward for better oncology treatments for pancreatic and colorectal cancer patients, its stock recorded a surge by 5.44% and closed the previous day at $0.155.
